Form 4: Rapport Therapeutics Executive Sells Shares

Rapport Therapeutics Chief Development Officer, Yeleswaram Krishnaswamy, reported the sale of company stock totaling over 20,000 shares across multiple transactions.

Summary

• Yeleswaram Krishnaswamy, Chief Development Officer at Rapport Therapeutics, Inc., reported transactions involving the sale of common stock.
• These sales occurred on April 10, April 13, and April 14, 2026.
• A total of 500 shares were sold on April 10th at a price of $34.98.
• On April 13th, 9,165 shares were sold at a weighted average price of $34.974.
• On April 14th, 10,200 shares were sold at a weighted average price of $35.0781.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on December 10, 2025.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a slightly negative sentiment due to the insider selling, even though it was conducted under a pre-arranged trading plan.

Negatives

• The Chief Development Officer sold a significant number of shares, indicating a potential lack of confidence or a need for personal liquidity.

Risks

• Insider selling can sometimes be interpreted by the market as a negative signal, potentially impacting investor sentiment and stock price.

Future Outlook

No forward-looking statements or guidance are present in this filing.

Management Comments

• The transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025.
• The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.

Industry Context

StockSavvy.ai notes that Form 4 filings, detailing insider transactions, are crucial for understanding executive sentiment. While sales can be for personal reasons or part of pre-arranged plans like Rule 10b5-1, significant selling by key officers warrants investor attention.

Stakeholder Impact

• Shareholders may view the insider selling as a potential negative signal, possibly leading to increased scrutiny of the company's performance and future prospects.

Key Dates

Recommendation

The filing indicates insider selling under a Rule 10b5-1 plan, which mitigates immediate concern. However, significant sales by a Chief Development Officer warrant a cautious 'hold' approach pending further company performance updates.

Keywords

Rapport Therapeutics, RAPP, Form 4, Insider Trading, Stock Sale, Rule 10b5-1, Yeleswaram Krishnaswamy, Chief Development Officer